Replimune Group (NASDAQ:REPL) Insider Christopher Sarchi Sells 6,500 Shares of Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Christopher Sarchi sold 6,500 shares of the business’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total transaction of $52,065.00. Following the transaction, the insider owned 151,588 shares in the company, valued at approximately $1,214,219.88. This trade represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Replimune Group Stock Performance

Shares of REPL stock opened at $8.54 on Tuesday. The firm has a market cap of $705.15 million, a price-to-earnings ratio of -2.48 and a beta of 0.74. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. Replimune Group, Inc. has a 52 week low of $2.68 and a 52 week high of $13.24. The firm’s 50-day simple moving average is $7.61 and its two-hundred day simple moving average is $7.89.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.08. As a group, equities analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Institutional Investors Weigh In On Replimune Group

A number of large investors have recently added to or reduced their stakes in the company. Invesco Ltd. grew its holdings in Replimune Group by 297.3% in the 4th quarter. Invesco Ltd. now owns 613,015 shares of the company’s stock worth $5,959,000 after acquiring an additional 458,714 shares during the last quarter. XTX Topco Ltd bought a new stake in Replimune Group in the 4th quarter worth $322,000. Virtus Investment Advisers LLC lifted its position in shares of Replimune Group by 127.0% in the 4th quarter. Virtus Investment Advisers LLC now owns 26,133 shares of the company’s stock worth $254,000 after purchasing an additional 14,622 shares during the period. SummitTX Capital L.P. bought a new stake in shares of Replimune Group during the 4th quarter valued at about $1,058,000. Finally, Susquehanna Portfolio Strategies LLC bought a new stake in shares of Replimune Group during the 4th quarter valued at about $650,000. Institutional investors own 92.53% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on REPL. Weiss Ratings reissued a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. Wedbush raised their price target on shares of Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. Finally, Piper Sandler raised their price target on shares of Replimune Group from $13.00 to $14.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $10.00.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.